The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
A correction has been published: N Engl J Med 2008;359(8):877.

Review Article
Medical Progress
PreviousPrevious
Volume 359:492-507 July 31, 2008 Number 5
NextNext

Malignant Gliomas in Adults
Patrick Y. Wen, M.D., and Santosh Kesari, M.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set
-CME Exam
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
-PubMed Citation
Malignant gliomas account for approximately 70% of the 22,500 new cases of malignant primary brain tumors that are diagnosed in adults in the United States each year.1,2,3 Although relatively uncommon, malignant gliomas are associated with disproportionately high morbidity and mortality. Despite optimal treatment, the median survival is only 12 to 15 months for patients with glioblastomas and 2 to 5 years for patients with anaplastic gliomas. Recently, there have been important advances in our understanding of the molecular pathogenesis of malignant gliomas and progress in treating them. This review summarizes the diagnosis and management of these tumors in adults and . . . [Full Text of this Article]

Epidemiologic Features

Pathological Features

Molecular Pathogenesis

Deregulated Growth Factor Signaling

Role of Stem Cells in Pathogenesis and Resistance to Therapy

Diagnosis

Clinical Presentation

Imaging

Treatment

General Medical Management

Specific Therapy for Newly Diagnosed Malignant Gliomas

Therapy for Anaplastic Gliomas

Therapy for Recurrent Malignant Gliomas

Investigational Therapies

Targeted Molecular Therapies

Antiangiogenic Agents

Other Therapies

Prognostic Factors

Summary


Source Information

From the Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital; and the Center for Neuro-Oncology, Dana–Farber Cancer Institute — both in Boston.

Address reprint requests to Dr. Wen at the Center for Neuro-Oncology, Dana–Farber/Brigham and Women's Cancer Center, SW430D, 44 Binney St., Boston, MA 02115, or at pwen@partners.org.


Related Letters:

Malignant Gliomas in Adults
Meyer M. A., Wen P. Y., Kesari S.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1850, Oct 23, 2008. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.